http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10857178-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_212d6c91654af2b0974f0531f3cc8f26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42d829f33928487d89cbbaf43248e803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62ab80664e81bcb29c91ac135e5e70f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f3e033374f35e08e72eea5ff3cbdcf90 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-244 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-244 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2008-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fb8d22d1d06b44404aa63d053bca486 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1fa0077555248a7b1eb60611523fbd8d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2da8b4c7e3fa056999bdb3b7fbddfd55 |
| publicationDate | 2020-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-10857178-B2 |
| titleOfInvention | Cerium oxide nanoparticles for treatment and prevention of Alzheimer's disease, Parkinson's disease, and disorders associated with free radical production and/or mitochondrial dysfunction |
| abstract | Cerium oxide nanoparticles (CeONP) can be used to treat or prevent neurodegenerative diseases, including for example Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, AIDS-related dementia, ALS, progressive supranuclear palsy, and encephalitis, as well as mitochondrial diseases and diseases associated with mitochondrial damage. In particular, CeONP having an average size of about 2 nm to about 100 nm can be administered in an amount sufficient to block production of hydroxyl or superoxide radicals, block free radical production by Aβ(1-42), block Aβ(1-42)-induced neuronal death, block Aβ(1-42)-induced [Ca2+]i dysfunction in neurons, block Aβ(1-42)-induced lipid peroxidation, decrease loss of dopaminergic neurotransmission, or reduce mitochondrial dysfunction in a cell. CeONP can also be effective in treating conditions involving toxic exposures to compounds that induce mitochondrial dysfunction, such as rotenone, cyanide, carbon monoxide, polychlorinated biphenyls (PCBs) and other mitochondrial toxins. |
| priorityDate | 2005-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 71.